Adjuvant treatment of colorectal cancer

Annual Review of Medicine

Volumn 48, Issue , 1997, Pages 191-202

  Saltz, Leonard B ^a   Kelsen, David P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant; Chemotherapy; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW;

CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031051207     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.48.1.191     Document Type: Review

References (49)

1. Parker SL, Tong T, Bolden S, Wingo PA. 1996. Cancer statistics, 1996. Cancer J. Clin. 46:5-27
2. August DA, Ottow RT, Sugarbaker PH. 1984. Clinical perspectives on human colorectal cancer metastases. Cancer Metastases Rev. 3:303-24
3. Willett CG, Tepper JE, Cohen AM. 1984. Failure patterns following curative resection of colonic carcinoma. Ann. Surg. 200: 685-90
4. Minsky BD, Mies C, Rich TA, et al. 1988. Potentially curative surgery of colon cancer: patterns of failure and survival. J. Clin. Oncol. 6:106-18
5. Mrazek R, Economou S, McDonald GO, et al. 1959. Prophylactic and adjuvant use of nitrogen mustard in the surgical treatment of cancer. Ann. Surg. 150:745-55
6. Holden GA, Dixon WJ, Kuzma JW. 1967. The use of triethylene thiophosphoramide as an adjuvant to the surgical treatment of colorectal carcinoma. Ann. Surg. 165: 481-89
7. Higgins GA, Humphrey EW, Juler GL, et al. 1976. Adjuvant chemotherapy in the surgical treatment of large bowel cancer. Cancer 38:1461
8. Gastrointestinal Tumor Study Group. 1984. Adjuvant therapy of colon cancer: results of a prospectively randomized trial. N. Engl. J. Med. 310:737-42
9. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. 1988. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 259:3571-78
10. Wolmark N, Fisher B, Rockette H, et al. 1988. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP Protocol C-01. J. Natl. Cancer Inst. 80:30-36
11. Verhaegen H, DeCree J, DeCock W, et al. 1982. Levamisole therapy in patients with colorectal cancer. In Immunotherapy of Human Cancer, ed. WD Terry, SA Rosenberg, pp. 225-29. New York: Elsevier
12. Laurie JA, Moertel CG, Fleming TR, et al. 1989. Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J. Clin. Oncol. 7:1447-56
13. Moertel CG, Fleming TR, Macdonald JS, et al. 1995. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med. 122:321-26
14. 2 colon cancer. J. Clin. Oncol. 13:2936-43
15. NIH Consensus Conference. 1990. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-50
16. Willet CG, Tepper JE, Cohen AM. 1985. Obstructive and perforative colonie carcinoma: patterns of failure. J. Clin. Oncol. 3:379-84
17. Takimoto CH. 1995. Enigma of fluorouracil and levamisole. J. Natl. Cancer Inst. 87:471-73
18. Mayer RJ. 1990. Does adjuvant therapy work in colon cancer? N. Engl. J. Med. 322:399-401
19. Moertel CG. 1994. Chemotherapy of colorectal cancer. N. Engl. J. Med. 330:1136
20. Wolmark N, Rockette H, Fisher B, et al. 1993. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J. Clin. Oncol. 11:1879-87
21. International Multicenter Pooled Analysis of Colon Cancer Trials Investigators. 1995. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: 939-44
22. Wolmark N, Rockette H, Mamounas EP, et al. 1996. The relative efficacy of 5FU + leucovorin, 5FU + levamisole, and 5FU + leucovorin + levamisole in patients with Dukes B and C carcinoma of the colon: first report of NSABP C-04. Proc. Am. Soc. Clin. Oncol. 15:205 (Abstr.)
23. O'Connell MJ, Laurie JA, Shepard L, et al. 1996. A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of the north central cancer treatment group and the national cancer institute of Canada clinical trials group. Proc. Am. Soc. Clin. Oncol 15:209 (Abstr.)
24. Haller DG, Catalano PJ, MacDonald JS, et al. 1996. Fluorouracil (FU), Leucovorin (LV), and Levamisole (LEV) adjuvant therapy for colon cancer: preliminary results of INT-0089. Proc. Am. Soc. Clin. Oncol. 15: 211 (Abstr.)
25. Fisher ER, Turnbull RB. 1955. The cytologic demonstration and significance of tumor cells in the mesenteric venous blood in patients with colorectal carcinoma. Surg. Gynecol. Obstet. 100:102-8
26. Almersjo O, Brandberg A, Gustavsson B. 1975. Concentration of biologically active 5-fluorouracil in the general circulation during continuous portal infusion in man. Cancer Lett. 1:113
27. Taylor I, Rowling JT, West C. 1979. Adjuvant cytotoxic liver perfusion for colorectal cancer. Br. J. Surg. 66:833-37
28. Weber W, Laffer U, Metzger U. 1993. Adjuvant portal liver infusion with 5-fluorouracil and mitomycin in colorectal cancer. Anticancer Res. 13(5C):1839-40
29. Swiss Group for Clinical Cancer Research. 1995. Long term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 345:349-52
30. Wolmark N, Rockette H, Wickerman DL, et al. 1990. Adjuvant therapy of Dukes A, B, and C adenocarcinoma of the colon with portal vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J. Clin. Oncol. 8:1466-75
31. Speyer JL, Sugarbaker PH, Collins JM, et al. 1981. Portal levels and hepatic clearance of 5-fluorouracil after intraportal administration in humans. Cancer Res. 41: 1916-22
32. Archer SG, McCulloch RK, Gray BN. 1989. A comparative study of the pharmacokinetics of continuous portal vein infusion versus intraperitoneal infusion of 5-fluorouracil. Reg. Cancer Treat. 2:105-11
33. Speyer JL, Collins JM, Dedrick RL, et al. 1980. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 40:567-72
34. Sugarbaker PH, Gianola FJ, Speyer JC, et al. 1985. Prospective randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 98: 414-21
35. Kelsen DP, Saltz L, Cohen AM, et al. 1994. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. Cancer 74:2224-33
36. Jain RK. 1990. Physiological barriers to the delivery of monoclonal antibodies and other macromoloecules in tumors. Cancer Res. 50:2741-51
37. Herlyn D, Koprowsky H. 1982. 1gG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc. Natl. Acad. Sci. USA 79: 4761-65
38. Gottlinger HG, Funke I, Johnson JP, et al. 1986. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumour therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int. J. Cancer 38: 27-53
39. Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. 1980. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 40: 717-21
40. Mellstedt H, Frodin JJE, Masuccci G. 1991. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin. Oncol. 2:462-77
41. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al. 1994. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 343:1177-83
42. O'Boyle KP, Zamore R, Adluri S, et al. 1992. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to Sialylated Tn. Cancer Res. 52:5663-67
43. Hoover HC, Brandhorst JS, Peters LC, et al. 1993. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase II prospectively randomized trial. J. Clin. Oncol. 11:390-99
44. Moertel CG. 1993. Vaccine adjuvant therapy for colorectal cancer: "very dramatic" or ho-hum? J. Clin. Oncol. 11:385-86
45. Gastrointestinal Tumor Study Group. 1985. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N. Engl. J. Med. 312:1465-72
46. Douglas HO, Moertel CG, Mayer RJ, et al. 1986. Survival after postoperative combination treatment for rectal cancer. N. Engl. J. Med. 315:1294-95
47. Krook JE, Moertel CG, Gunderson LL, et al. 1991. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med. 324: 709-15
48. O'Connell MJ, Martenson JA, Weiand HS, et al. 1994. Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med. 331: 502-7
49. Minsky BD, Cohen AM, Kemeny N, et al. 1992. Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. J. Clin. Oncol. 10: 1218-24